These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 25791993)
1. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease. Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993 [TBL] [Abstract][Full Text] [Related]
2. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923 [TBL] [Abstract][Full Text] [Related]
3. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs. Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440 [TBL] [Abstract][Full Text] [Related]
4. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666 [TBL] [Abstract][Full Text] [Related]
5. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927 [TBL] [Abstract][Full Text] [Related]
7. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112 [TBL] [Abstract][Full Text] [Related]
8. Quantification and discriminative power of Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal DAT changes measured with [ Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016 [TBL] [Abstract][Full Text] [Related]
10. Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand Lizana H; Johansson L; Axelsson J; Larsson A; Ögren M; Linder J; Halldin C; Varrone A; Mo SJ J Nucl Med; 2018 Aug; 59(8):1275-1280. PubMed ID: 29348315 [No Abstract] [Full Text] [Related]
11. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I. Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293 [TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. Varrone A; Tóth M; Steiger C; Takano A; Guilloteau D; Ichise M; Gulyás B; Halldin C J Nucl Med; 2011 Jan; 52(1):132-9. PubMed ID: 21189414 [TBL] [Abstract][Full Text] [Related]
13. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Schou M; Steiger C; Varrone A; Guilloteau D; Halldin C Bioorg Med Chem Lett; 2009 Aug; 19(16):4843-5. PubMed ID: 19577467 [TBL] [Abstract][Full Text] [Related]
15. Reliability of dopamine transporter PET measurements with [ Kerstens VS; Fazio P; Sundgren M; Matheson GJ; Franzén E; Halldin C; Cervenka S; Svenningsson P; Varrone A EJNMMI Res; 2020 Aug; 10(1):95. PubMed ID: 32797307 [TBL] [Abstract][Full Text] [Related]
16. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT. Ziebell M Dan Med Bull; 2011 May; 58(5):B4279. PubMed ID: 21535991 [TBL] [Abstract][Full Text] [Related]
18. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779 [TBL] [Abstract][Full Text] [Related]
19. Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies. Varrone A; Gulyás B; Takano A; Stabin MG; Jonsson C; Halldin C Nucl Med Biol; 2012 Feb; 39(2):295-303. PubMed ID: 22033024 [TBL] [Abstract][Full Text] [Related]
20. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. Varrone A; Stepanov V; Nakao R; Tóth M; Gulyás B; Emond P; Deloye JB; Vercouillie J; Stabin MG; Jonsson C; Guilloteau D; Halldin C J Nucl Med; 2011 Aug; 52(8):1313-21. PubMed ID: 21764797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]